Current Perspectives on Ranibizumab

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2015 Apr 8

PMID 25848203

Citations 18

Authors

Vaidehi S Dedania

Sophie J Bakri

Affiliations

Soon will be listed here.

Abstract

Background: This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME).

Results: The data from 12 major Phase III studies: six studies in patients with neovascular AMD, two studies in patients with ME from RVO, and four studies in patients with DME demonstrate significant improvement in vision in patients undergoing treatment with intravitreal ranibizumab over patients receiving no treatment or receiving only grid laser. These effects are achieved with low incidences of ocular and nonocular adverse events.

Conclusion: Intravitreal ranibizumab is a highly effective and safe therapy for improving vision and reducing vision loss in patients with neovascular AMD, ME from RVO, and DME. Patients generally require long-term treatment although some data show that frequency of treatment necessary to maintain visual outcomes decreases over time.

Citing Articles

Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody.

Huang C, Kaur A, Ji L, Tian H, Webster K, Li W Gene Ther. 2024; 31(11-12):587-593.

PMID: 39333408 PMC: 11720169. DOI: 10.1038/s41434-024-00491-9.

Novel fabrication of anti-VEGF drug ranibizumab loaded PLGA/PLA co-polymeric nanomicelles for long-acting intraocular delivery in the treatment of age-related macular degeneration therapy.

Xu J, Wang Y, Liu X Regen Ther. 2024; 26:620-634.

PMID: 39281109 PMC: 11399609. DOI: 10.1016/j.reth.2024.06.019.

Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy.

Huang C, Waduge P, Kaur A, Tian H, Weng C, Stout J Int J Mol Sci. 2024; 25(17).

PMID: 39273454 PMC: 11394726. DOI: 10.3390/ijms25179507.

Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice.

Huang C, Ji L, Kaur A, Tian H, Waduge P, Webster K Biomedicines. 2023; 11(7).

PMID: 37509549 PMC: 10377229. DOI: 10.3390/biomedicines11071910.

Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy.

Ji L, Waduge P, Wu Y, Huang C, Kaur A, Oliveira P Int J Mol Sci. 2023; 24(13).

PMID: 37445707 PMC: 10341987. DOI: 10.3390/ijms241310531.

References

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

Heier J, Brown D, Chong V, Korobelnik J, Kaiser P, Nguyen Q . Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119(12):2537-48. DOI: 10.1016/j.ophtha.2012.09.006. View

Brown D, Campochiaro P, Bhisitkul R, Ho A, Gray S, Saroj N . Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011; 118(8):1594-602. DOI: 10.1016/j.ophtha.2011.02.022. View

Seddon J, Chen C . The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2004; 44(4):17-39. DOI: 10.1097/00004397-200404440-00004. View

Abraham P, Yue H, Wilson L . Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010; 150(3):315-324.e1. DOI: 10.1016/j.ajo.2010.04.011. View

Campochiaro P, Brown D, Awh C, Lee S, Gray S, Saroj N . Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011; 118(10):2041-9. DOI: 10.1016/j.ophtha.2011.02.038. View

Singer M, Awh C, Sadda S, Freeman W, Antoszyk A, Wong P . HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012; 119(6):1175-83. DOI: 10.1016/j.ophtha.2011.12.016. View

Adamis A, Aiello L, DAmato R . Angiogenesis and ophthalmic disease. Angiogenesis. 2003; 3(1):9-14. DOI: 10.1023/a:1009071601454. View

Grunwald J, Daniel E, Huang J, Ying G, Maguire M, Toth C . Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013; 121(1):150-161. PMC: 3892560. DOI: 10.1016/j.ophtha.2013.08.015. View

10.

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang G, Massin P, Schlingemann R . The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4):615-25. DOI: 10.1016/j.ophtha.2011.01.031. View

11.

. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995; 102(10):1425-33. DOI: 10.1016/s0161-6420(95)30849-4. View

12.

Busbee B, Ho A, Brown D, Heier J, Suner I, Li Z . Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120(5):1046-56. DOI: 10.1016/j.ophtha.2012.10.014. View

13.

Elman M, Ayala A, Bressler N, Browning D, Flaxel C, Glassman A . Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2014; 122(2):375-81. PMC: 4520307. DOI: 10.1016/j.ophtha.2014.08.047. View

14.

Stein J, Newman-Casey P, Mrinalini T, Lee P, Hutton D . Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology. 2014; 121(4):936-45. PMC: 4109727. DOI: 10.1016/j.ophtha.2013.10.037. View

15.

Grisanti S, Tatar O . The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008; 27(4):372-90. DOI: 10.1016/j.preteyeres.2008.05.002. View

16.

Brown D, Kaiser P, Michels M, Soubrane G, Heier J, Kim R . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432-44. DOI: 10.1056/NEJMoa062655. View

17.

Varma R, Bressler N, Suner I, Lee P, Dolan C, Ward J . Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012; 119(10):2108-18. DOI: 10.1016/j.ophtha.2012.05.017. View

18.

Adamis A, Shima D . The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005; 25(2):111-8. DOI: 10.1097/00006982-200502000-00001. View

19.

Grunwald J, Pistilli M, Ying G, Maguire M, Daniel E, Martin D . Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 122(4):809-16. PMC: 4372487. DOI: 10.1016/j.ophtha.2014.11.007. View

20.

Boyer D, Heier J, Brown D, Francom S, Ianchulev T, Rubio R . A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009; 116(9):1731-9. DOI: 10.1016/j.ophtha.2009.05.024. View